Compare SRI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRI | SGMT |
|---|---|---|
| Founded | 1965 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 169.4M |
| IPO Year | 1997 | 2021 |
| Metric | SRI | SGMT |
|---|---|---|
| Price | $5.57 | $5.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $16.00 | ★ $26.38 |
| AVG Volume (30 Days) | 191.7K | ★ 310.8K |
| Earning Date | 06-12-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $824,444,000.00 | $2,000,000.00 |
| Revenue This Year | $7.42 | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $3.54 | $1.73 |
| 52 Week High | $9.71 | $11.41 |
| Indicator | SRI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 26.58 | 41.28 |
| Support Level | $5.58 | $4.97 |
| Resistance Level | $6.35 | $6.62 |
| Average True Range (ATR) | 0.42 | 0.28 |
| MACD | -0.31 | -0.04 |
| Stochastic Oscillator | 4.76 | 8.39 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.